Innova Captab Limited Approves Financial Revisions and Greenlights Major Manufacturing Facility Expansion
Innova Captab Limited has announced the approval of revised consolidated and standalone financial results for the quarter and financial year ended March 31, 2026. The company's Board of Directors also approved a significant brownfield expansion plan for its manufacturing facility located in Baddi, Himachal Pradesh.The company’s decisions, finalized following the Board meeting on August 21, 2026, include making necessary adjustments to previous financial statements and outlining future capacity additions at its key operational site.
Financial Results Summary
Innova Captab Limited reported comprehensive results for the quarter and year ended March 31, 2026. The company's consolidated financial performance metrics are detailed below:| Metric | Consolidated (FY Ended March 31, 2026) | Quarterly (Q Ended March 31, 2026) |
|---|---|---|
| Total Income | 16,374.38 million | 4,493.66 million |
| Profit for the Period/Year | 1,431.83 million | 403.49 million |
| Total Comprehensive Income | 1,435.89 million | 405.93 million |
For the standalone results, the company reported:
| Metric | Standalone (FY Ended March 31, 2026) | Quarterly (Q Ended March 31, 2026) |
|---|---|---|
| Total Income | 13,120.57 million | 3,609.57 million |
| Profit for the Period/Year | 849.31 million | 224.01 million |
| Total Comprehensive Income | 848.76 million | 227.42 million |
Brownfield Expansion Approved
In addition to reviewing the financial results, the Board of Directors approved a brownfield expansion of the existing manufacturing facility located at Baddi, Himachal Pradesh.The proposed project involves the addition of two Oral Solid Dosage (Tablets/Capsules) production lines. This capacity increase is expected to be completed within approximately 18 to 22 months. The investment required for this expansion is estimated at ₹45,00,00,000.00 and will be financed through a combination of bank credit facilities and the company's internal accruals.
The existing capacity at the facility includes two production lines for Oral Solid Dosage (Tablets/Capsules) and one production line for Ointments, with current utilization estimated between 85% to 90%. The rationale behind the expansion is to improve operational efficiency, optimize manufacturing costs, and support long-term growth.
Audit and Compliance Updates
The statutory auditors of Innova Captab Limited issued a revised audit report with an unmodified opinion on both the consolidated and standalone financial results for the quarter and financial year ended March 31, 2026.One entity’s performance within the Group was noted in the revised consolidated financial results, showing total assets (before consolidation adjustments) of ₹0.34 million as at March 31, 2026, with a net loss after tax (before consolidation adjustments) of ₹0.43 million for the year ended on that date.
INNOVACAP Stock Price Movement
Innova Captab Limited edged higher on Friday, gaining 0.35% and closing at ₹1088.5. The stock completed the trading period having accumulated a total traded volume of 78,410 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.